You are here: Fairness.com > Resources > Drug Investors Lose Patience

Drug Investors Lose Patience

Date: March 10, 2009

Author: Andrew Pollack

QUOTE: Now, with cash scarce, credit tight and big drug companies like Merck intent on branching into biotechnology themselves, struggling start-ups may no longer get second and third chances to succeed.

• Read it: New York Times
• Tell a friend
• Add a Comment*

Article MetaInformation:

Key People:

Key Organizations:

• Gilead Sciences
• Merck & Co.
• New York Times Company
• VaxGen

Subject & Geographic Categories:

• Businesses & Organizations
  • Industry-Specific Issues
    • Chemicals
  • Organizational Structure
  • Purchasing / Procurement

• North America
  • United States of America/USA

Comments:

none

• Add a Comment*

*User comments are posted without Fairness.com LLC's prior review or approval, and Fairness.com LLC takes no responsibility for them; please see our Conditions of Service Agreement.

Please send your comments and suggestions to the Webmaster. © copyright 1999-2009, Fairness.com LLC.
"Fairness.com" and "Life isn't fair... but we're working on it" are service marks of Fairness.com LLC. All rights reserved.